Literature DB >> 21421467

Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?

Carmen Balañá, Olatz Etxaniz, Cristina Bugés, Alex Martínez.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21421467     DOI： 10.1007/s12094-011-0642-9

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


× No keyword cloud information.
  9 in total

1.  Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.

Authors:  M Brada; K Hoang-Xuan; R Rampling; P Y Dietrich; L Y Dirix; D Macdonald; J J Heimans; B A Zonnenberg; J M Bravo-Marques; R Henriksson; R Stupp; N Yue; J Bruner; M Dugan; S Rao; S Zaknoen
Journal:  Ann Oncol       Date:  2001-02       Impact factor: 32.976

2.  Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.

Authors:  W K Yung; M D Prados; R Yaya-Tur; S S Rosenfeld; M Brada; H S Friedman; R Albright; J Olson; S M Chang; A M O'Neill; A H Friedman; J Bruner; N Yue; M Dugan; S Zaknoen; V A Levin
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

3.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

Review 4.  Histopathology, classification, and grading of gliomas.

Authors:  P Kleihues; F Soylemezoglu; B Schäuble; B W Scheithauer; P C Burger
Journal:  Glia       Date:  1995-11       Impact factor: 7.452

Review 5.  Epidemiology of brain tumors.

Authors:  James L Fisher; Judith A Schwartzbaum; Margaret Wrensch; Joseph L Wiemels
Journal:  Neurol Clin       Date:  2007-11       Impact factor: 3.806

6.  Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group.

Authors:  H Brem; S Piantadosi; P C Burger; M Walker; R Selker; N A Vick; K Black; M Sisti; S Brem; G Mohr
Journal:  Lancet       Date:  1995-04-22       Impact factor: 79.321

7.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

Authors:  Teri N Kreisl; Lyndon Kim; Kraig Moore; Paul Duic; Cheryl Royce; Irene Stroud; Nancy Garren; Megan Mackey; John A Butman; Kevin Camphausen; John Park; Paul S Albert; Howard A Fine
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

8.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors:  Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

9.  A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.

Authors:  W K Yung; R E Albright; J Olson; R Fredericks; K Fink; M D Prados; M Brada; A Spence; R J Hohl; W Shapiro; M Glantz; H Greenberg; R G Selker; N A Vick; R Rampling; H Friedman; P Phillips; J Bruner; N Yue; D Osoba; S Zaknoen; V A Levin
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640
  9 in total
  5 in total

1.  Efficacy and safety of bevacizumab for the treatment of glioblastoma.

Authors:  Zhiyun Yu; Gang Zhao; Zhonghua Zhang; Yunqian Li; Yong Chen; Nan Wang; Zhongying Zhao; Guifang Xie
Journal:  Exp Ther Med       Date:  2015-12-16       Impact factor: 2.447

2.  High-dose salvage re-irradiation for recurrent/progressive adult diffuse glioma: healing or hurting?

Authors:  T Gupta; M Maitre; P Maitre; J S Goda; R Krishnatry; A Chatterjee; A Moiyadi; P Shetty; S Epari; A Sahay; V Patil; R Jalali
Journal:  Clin Transl Oncol       Date:  2021-02-02       Impact factor: 3.405

3.  Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges.

Authors:  Gazanfar Rahmathulla; Elizabeth J Hovey; Neda Hashemi-Sadraei; Manmeet S Ahluwalia
Journal:  Onco Targets Ther       Date:  2013-04-15       Impact factor: 4.147

4.  Pretreatment inflammatory indices predict Bevacizumab response in recurrent Glioma.

Authors:  Alicia Martínez-González; Raquel Cabrera; Marta Lloret; Pedro C Lara
Journal:  Cancer Drug Resist       Date:  2020-08-07

5.  Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: an exploratory randomized phase II trial.

Authors:  Elizabeth J Hovey; Kathryn M Field; Mark A Rosenthal; Elizabeth H Barnes; Lawrence Cher; Anna K Nowak; Helen Wheeler; Kate Sawkins; Ann Livingstone; Pramit Phal; Christine Goh; John Simes
Journal:  Neurooncol Pract       Date:  2017-05-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.